Clinical trials: Skin Testing
No Protrusion, No Open Wound
The Sponsor Assigns Test Products to Six Skin Areas According to a Concealed Randomization Schedule; Neither the Evaluating Physicians Nor the Participants Know Which Product is Applied to Which Site, Preventing Bias.
This is a single-center, double-blind, randomized, and controlled study. The sponsor keeps the allocation of products to the six test sites confidential.
- Conditions
- No Protrusion, No Open Wound, No Severe Allergic Reaction, No Scar
- Trial name
- NCT07154004
- Testing
- Test Serum 897222 210, Test Serum 897222 212, Test Serum 897250 39
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BEIJING YUANBEN INFORMATION CONSULTING CO., LTD
Type I Hypersensitivity
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00104390
- Testing
- Grass MATA MPL
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Allergy Therapeutics
Breast Cancer, Metastatic, Breast Cancer Invasive
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
- Conditions
- Breast Cancer, Metastatic, Breast Cancer Invasive, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Trial name
- PROBE-CTC (NCT06807502)
- Testing
- The DM/DIV ScreenCell is the experimental product studied during this research
- Where
- France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- ScreenCell
Rheumatoid Arthritis
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Study Design \& Objectives: Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with a clinical follow-up between 12 and 14 weeks.
- Trial name
- PRINT (NCT01299545)
- Where
- 37 sites in Canada, France and 6 more
- Volunteers
- 123 people
- Sponsor
- TcLand Expression S.A.
Topical Antisepsis
Test for Pre Operative Skin Preparations
Compare 2 application techniques of ChloraPrep Swabstick--3 swabsticks at once versus 3 swabsticks used sequentially. Hibiclens applied according to the manufacturer's directions.
- Trial name
- NCT00799812
- Testing
- CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once)., CHG 2% w/v & IPA 70% v/v swab applied sequentially, Aqueous CHG 4% w/v applied according to mfr's directions
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- C. R. Bard
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery.
- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06324357
- Testing
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine
- Where
- 104 sites in United States, Belgium and 8 more
- Volunteers
- 910 people
- Sponsor
- Boehringer Ingelheim
Allergy Skin, Allergy
NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test
The objective of this study is to investigate the potential of NeoMatriXTM Wound Matrix to cause an allergic response to healthy volunteers using a skin prick test.
- Conditions
- Allergy Skin, Allergy, Dermatitis, Allergic Contact
- Trial name
- NCT03522675
- Testing
- NeoMatriX Wound MatriX Collagen Dressing
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- NeXtGen Biologics, Inc.
Skin Aging on Face, Skin Care Dermocosmetics
Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging
Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+).
- Conditions
- Skin Aging on Face, Skin Care Dermocosmetics, Skin Care, Fine Lines and Wrinkles
- Trial name
- NR-RADIANCE (NCT07774000)
- Testing
- Topical niacinamide riboside
- Where
- South Africa
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- ChromaDex, Inc.
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Diabetic Foot Ulcers
WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test on DFU
The purpose of this trial is to determine if wounds with elevated protease activity (EPA) treated with targeted interventions such as protease modulating therapies can improve clinical and economic outcomes.
- Trial name
- NCT01537016
- Testing
- PROMOGRAN, Tielle
- Where
- 5 sites in United States, Germany and 3 more
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Systagenix Wound Management
Psoriasis
Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis
The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.
- Trial name
- NCT01368887
- Testing
- DPS-102, Calcipotriol Monotherapy, Nicotinamide Monotherapy
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- DermiPsor, Ltd.
Healthy
Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
In the tests, small sample of clinical study about Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 ( Recombination EC Allergen） healthy adults was carried out.
- Trial name
- NCT01999231
- Testing
- ESAT6-CFP10
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Breast Carcinoma
Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study
This study investigates if a new type of test called Droplet-BC screening test can classify breast cancer patients from non-cancer volunteers by circulating small-noncoding RNA in the blood with a statistical validity.
- Trial name
- NCT04671498
- Testing
- Biospecimen Collection, Droplet-BC Test, Electronic Health Record Review
- Where
- 3 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Preferred Medicine, Inc
Cervical Cancer, Genital Warts
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
The primary purpose of the study is to test the safety of HPV Vaccine in Women
- Trial name
- FUTURE (NCT00517309)
- Testing
- V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years
- Volunteers
- 1,877 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair
- Trial name
- NCT00624832
- Testing
- Xolair
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis
Breast Cancer, Abnormal Mammogram, Unspecified
Breath Test to Predict Breast Cancer and Outcome of Mammography
To validate a breath test that predicts risk of breast cancer and an abnormal mammogram.
- Trial name
- NCT04755829
- Testing
- BreathX test for breath VOCs
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Menssana Research, Inc.
Melanoma
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy.
- Trial name
- NCT00658437
- Testing
- CY-503
- Where
- 4 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Cytavis Biopharma GmbH
Hidradenitis Suppurativa
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD EXT (NCT04901195)
- Testing
- Bimekizumab
- Where
- 145 sites in United States, Australia and 17 more
- Volunteers
- 658 people
- Sponsor
- UCB Biopharma SRL
Breast Cancer
Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning
This study will explore provider's screening and management practices for eligibility for neoadjuvant therapy from baseline to following the project intervention (use of a novel existing technology, the Carevive Care Planning…
- Trial name
- NCT03161600
- Testing
- Carevive CPS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Erythema, Sensitisation
Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
The primary objective of this study was to assess the sensitization potential of Omeza Collagen Matrix compared to that of a negative control based on a Modified Human Repeat Insult Patch Test.
- Trial name
- NCT04510675
- Testing
- Test Article, Negative Control
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Omeza, LLC